Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.58 -0.01 (-0.01%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.12 PB Ratio: 1.76 GF Score: 85/100

Q3 2020 Jazz Pharmaceuticals PLC Earnings Call Transcript

Nov 02, 2020 / 09:30PM GMT
Release Date Price: $147.25 (+2.19%)
Operator

Welcome to the Jazz Pharmaceuticals Plc Third Quarter 2020 Earnings Conference Call. (Operator Instructions)

I will now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Thank you, [Sino], and thanks to those of you joining our investor call. Today, we reported our third quarter 2020 financial results and updated our financial guidance for 2020. The press release and the slide presentation accompanying this call are available in the Investors section of our website.

On the call today are Bruce Cozadd, CEO; Renée Galá, CFO; Dan Swisher, President; and Rob Iannone, Executive Vice President, R&D. Joining for the Q&A session are Kim Sablich, Executive Vice President, General Manager of North America; Phil Jochelson, Neuroscience Therapeutic Head; Anne Borgman, Hematology and Oncology Therapeutic Head; Sam Pearce, Senior Vice President, Europe and International; Shawn Mindus, Senior Vice President, Strategy and Finance; and Larry Carter,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot